组蛋白修饰异常靶向免疫微环境促进B细胞淋巴瘤发生和发展的分子机制及靶向治疗进展  

Progress of molecular mechanisms and targeted therapies of aberrant histone modifications targeting the immune microenvironment of B-cell lymphoma

作　　者：李想[1] 纪濛濛 赵维莅[1] Li Xiang;Ji Mengmeng;Zhao Weili(Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,National Research Center for Translational Medicine at Shanghai,State Key Laboratory of Medical Genomics,Shanghai Institute of Hematology,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院、国家转化医学中心、医学基因组学国家重点实验室、上海血液学研究所,上海200025

出　　处：《白血病．淋巴瘤》2024年第5期309-313,共5页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金(82130004);申康重大临床研究项目(SHDC2020CR1032B)。

摘　　要：组蛋白修饰异常是B细胞淋巴瘤的重要发病机制,主要包括组蛋白甲基化和乙酰化异常。近年研究显示,组蛋白修饰异常可通过创造肿瘤支持性免疫微环境促进肿瘤细胞增殖、免疫逃逸等,从而促进淋巴瘤发生、发展。因此,逆转这些异常变化的表观遗传学药物是目前B细胞淋巴瘤的热点研究领域。文章将从B细胞淋巴瘤免疫微环境、组蛋白修饰异常靶向免疫微环境、免疫微生物改变及相关靶向治疗药物进展方面进行综述。Abnormal histone modifications,mainly including abnormal histone methylation and acetylation,play a crucial role in the pathogenesis of B-cell lymphoma.Recent studies have shown that abnormal histone modifications can promote the development of lymphoma by creating a tumor supportive immune microenvironment to promote tumor proliferation and immune escape.Therefore,drugs targeting histone modification gene abnormalities are currently a hot field of B-cell lymphoma.This article reviews the immune microenvironment of B-cell lymphoma,histone modification abnormalities targeting the immune microenvironment,immunomicrobial alterations,and advances in related targeted therapeutic agents.

关 键 词：淋巴瘤 大B细胞 弥漫性 组蛋白修饰 免疫抑制微环境 分子靶向治疗 

分 类 号：R733.1[医药卫生—肿瘤]